EP
AUPH icon

Essential Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Essential Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.09K Buy
182
+19
+12% +$304 ﹤0.01% 1781
2026
Q1 		$2.42K Buy
163
+5
+3% +$73 ﹤0.01% 1924
2025
Q4 		$2.52K Sell
158
-202
-56% -$2.86K ﹤0.01% 1724
2025
Q3 		$3.98K Buy
360
+337
+1,465% +$3.68K ﹤0.01% 1516
2025
Q2 		$195 Buy
+23
New +$184 ﹤0.01% 1952

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's AUPH Position: Q2 2026 in Review

Essential Partners increased its Aurinia Pharmaceuticals (AUPH) stake by 12% in Q2 2026, buying an estimated $304 and bringing the position to 182 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

Essential Partners first reported a position in AUPH in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.98K in Q3 2025. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Essential Partners held 182 shares of Aurinia Pharmaceuticals worth $3.09K as of Q2 2026.
  • Essential Partners bought 19 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $304.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1781 holding.
  • Essential Partners first reported a position in Aurinia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Aurinia Pharmaceuticals position peaked at $3.98K in Q3 2025.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.